A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian CancerTriple Negative Breast Cancer (TNBC)Cervical CancersSmall Cell Lung CancerHepatocellular Carcinoma (HCC)Colorectal CancerNon-Squamous Non-Small Cell Lung Cancer
- Interventions
- Drug: B1962
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06724263
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 1552
- Registration Number
- NCT05700591
- Locations
- 🇨🇳
Huizhou First Hospital, Guangdong, Guangdong, China
🇨🇳Tengzhou Central People's Hospital, Dezhou, Shandong, China
🇨🇳Shengli Oilfield Central Hospital, Dongying, Shandong, China
A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Drug: B1344Other: Placebo
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT05655221
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Inc., Glendale, California, United States
A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors
- Conditions
- Neoplasms Malignant
- Interventions
- Drug: B1962
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT05650385
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial
- Conditions
- Acute Ischaemic Stroke
- Interventions
- Drug: Recombinant human urokinaseDrug: AspirinDrug: rhPro-UK simulation agentDrug: Aspirin simulation agent
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 149
- Registration Number
- NCT03578822
- Locations
- 🇨🇳
XuanWu Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Harrison International Peace Hospital, Hengshui, Hebei, China
🇨🇳Tangshan Gongren Hospital, Tangshan, Hebei, China
Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)
- Conditions
- Acute Ischaemic Stroke
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 674
- Registration Number
- NCT03541668
- Locations
- 🇨🇳
XuanWu Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Luhe Hospital,Capital Medical University, Beijing, Beijing, China
🇨🇳The First Hospital of Handan, Handan, Hebei, China
A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism
- Conditions
- Acute Pulmonary Embolism
- Interventions
- Drug: Recombinant Human ProurokinaseDrug: Alteplase
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT03108833
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳Fuwai Hospital, Beijing, Beijing, China
🇨🇳Anzhen Hospital, Capital Medical University, Beijing, Beijing, China